Volume | 300,448 |
|
|||||
News | - | ||||||
Day High | 0.7127 | Low High |
|||||
Day Low | 0.6894 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Spruce Biosciences Inc | SPRB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.69 | 0.6894 | 0.7127 | 0.7012 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
671 | 300,448 | $ 0.6954568 | $ 208,949 | - | 0.6711 - 5.95 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:56:54 | 1 | $ 0.698199 | USD |
Spruce Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
28.5M | 40.71M | - | 10.09M | -47.92M | -1.18 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Spruce Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SPRB Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.693 | 0.7488 | 0.6711 | 0.7008046 | 628,077 | 0.0083 | 1.20% |
1 Month | 0.705 | 0.8698 | 0.6711 | 0.7621197 | 823,033 | -0.0037 | -0.52% |
3 Months | 3.38 | 5.95 | 0.6711 | 1.57 | 1,416,703 | -2.68 | -79.25% |
6 Months | 1.15 | 5.95 | 0.6711 | 1.65 | 764,352 | -0.4487 | -39.02% |
1 Year | 2.25 | 5.95 | 0.6711 | 1.73 | 435,576 | -1.55 | -68.83% |
3 Years | 17.00 | 17.58 | 0.6711 | 3.39 | 646,203 | -16.30 | -95.87% |
5 Years | 17.00 | 35.60 | 0.6711 | 3.75 | 560,001 | -16.30 | -95.87% |
Spruce Biosciences Description
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). |